Vital Biopharmaceutical Insights and Analytics

for Experts from Experts

Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.

Learn More

Niche Markets and Rare Diseases: Huntington’s Disease

Three therapies, Teva’s Huntexil, Auspex’s SD-809 and Raptor’s Procysbi, will likely receive regulatory approval for Huntington’s disease in the United States and the EU5 markets... Learn More

Asthma and COPD in Brazil and Mexico: The Impact of the Current Access Environment on the Uptake of Novel Biologics for Severe Asthma and Emerging Bronchodilators for COPD

Join us live on September 17, 2014... Learn More

View Webinar schedule and archive

Search Reports


See which reports have been searched on the most.


In the Spotlight

Join us in Boston

Come join us for an exciting one-day seminar.
Hear in-depth analysis of hot topics and trends concerning global oncology while engaging directly with Decision Resources Group analysts.

View the Agenda  |  Meet our expert speakers

Recent Reports [ view all ]

  • Type 2 Diabetes - 2014

    Last Updated 12 September 2014
    The type 2 diabetes therapy market will rapidly expand over our 2013-2023... Read More

  • Market Access Opportunities and Obstacles for Type 2 Diabetes in South Korea and Taiwan: Physician and Payer Insights

    South Korea and Taiwan have the most advanced healthcare systems among Asian countries, and both operate a universal... Read More

  • Crohn’s Disease and Ulcerative Colitis: U.S. Physician and Payer Perspectives on Established and Recently Launched Biologics, Emerging Novel Agents and Biosimilars

    Crohn’s disease (CD) and ulcerative colitis (UC) are two gastrointestinal autoimmune/inflammatory indications that... Read More

Decision Resources Group brands include: